Disclosed is the use of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof in the manufacture of a medicament for therapeutic treatments including weight management, decreasing food intake, inducing satiety or treating obesity, wherein: -the medicament is provided for oral administration at a dose of 20mg per day -the medicament is provided for administration in combination with a reduced-calorie diet -the subject has been selected for treatment as previously having been determined to have achieved at least 5% weight loss within 12 weeks of treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine at a dose of 20mg, and whereby achievement of at least 5% weight loss by week 12 correlates with a likelihood of the individual achieving an additional decrease in assessment of weight after about one year -wherein the subject has an initial BMI of over 27 prior to treatment
